Haematinic / Iron & Vitamin Supplement | Film-coated tablets | Pharmaceutical supply enquiries
Each film-coated tablet contains:
Therapeutic category: Haematinic / Iron, folate and vitamin B12 supplement.
Usage: Management of diagnosed nutritional deficiencies and anaemia where clinically appropriate, including in pregnancy under medical guidance.
SKU: Sodium Feredetate Folic Acid Vitamin B12 Tablets
Categories: Pharmaceutical Exporter India · Pharmaceutical Formulations India · WHO GMP Certified Formulations
Sodium Feredetate, Folic Acid & Vitamin B12 Tablets is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Sodium Feredetate, Folic Acid and Vitamin B12 tablets combine an iron source with nutrients involved in normal red blood cell production. The submitted composition specifies 231 mg sodium feredetate, providing 33 mg elemental iron, plus folic acid 1.5 mg and vitamin B12. These film-coated tablets are intended for use according to the approved product label and a clinician’s assessment of iron, folate and B12 status.
The submitted materials identify Healthy Life Pharma Pvt. Ltd. as manufacturer and Healthy Inc as exporter. Certifications and export capabilities require documentary confirmation.
| Product | Sodium Feredetate, Folic Acid & Vitamin B12 Tablets |
|---|---|
| Dosage form | Film-coated tablet |
| Sodium Feredetate BP | 231 mg (equivalent to elemental iron 33 mg) |
| Folic Acid BP | 1.5 mg |
| Vitamin B12 BP | 15 mg in supplied composition; 15 mcg in supplied description — confirm approved label before publishing |
| Therapeutic class | Haematinic / nutritional supplement |
| Manufacturer (as supplied) | Healthy Life Pharma Pvt. Ltd. |
| Exporter (as supplied) | Healthy Inc |
| Packaging / shelf life | Confirm from approved artwork and stability data |
Manufacturing considerations include compatibility of the iron chelate with folic acid and vitamin B12, control of blend uniformity for low-dose ingredients, appropriate film coating, and protection against moisture and light. The actual manufacturing process, coating system and packaging must be confirmed from approved batch records rather than assumed.
Relevant release and stability tests may include identity, assay of each active ingredient, content uniformity, dissolution or disintegration as applicable, impurities, microbial limits and stability under the approved storage conditions. Acceptance criteria must follow the applicable validated methods and registered specifications; no universal numerical limits are claimed here.
Iron supports haemoglobin synthesis; folate and vitamin B12 are essential for normal red blood cell development. This combination may be prescribed for deficiencies or anaemia when appropriate. Pregnancy supplementation must be individualized to nutritional status, local guidance and the approved formulation. The amount of elemental iron supplied by one tablet is 33 mg.
Claims of superior absorption or fewer gastrointestinal effects compared with every other iron preparation are not established here and should not be published without product-specific evidence.
For B2B enquiries, request the current product specification, approved artwork, certificate of analysis, stability data, manufacturing licence, and any market-specific registration dossier or certificates. WHO-GMP certification, Star Export House status, COPP and other certificates should be verified before advertising their availability.
Q: How much elemental iron does each tablet provide?
A: The stated 231 mg of sodium feredetate is equivalent to 33 mg elemental iron.
Q: Is the Vitamin B12 quantity 15 mg or 15 mcg?
A: The supplied composition says 15 mg, while the accompanying description says 15 mcg. This significant discrepancy must be resolved against the approved label before commercial use.
Q: Can it be used during pregnancy?
A: A clinician should confirm the need, formulation and dose. Do not assume the product is appropriate solely because it contains iron and folic acid.
Use only as directed by the prescribing clinician and the approved local label. Dose and duration depend on diagnosis, haemoglobin and iron studies, pregnancy status, concomitant medicines and tolerability. No fixed once- or twice-daily regimen is asserted for this unverified composition.
Oral iron may cause nausea, abdominal discomfort, constipation, diarrhoea and dark stools. Avoid unnecessary iron supplementation in iron-overload disorders. Iron can reduce absorption of certain medicines, including some tetracycline and quinolone antibiotics and levothyroxine; spacing and monitoring may be required. Keep iron-containing tablets away from children because overdose can be dangerous.
Label verification required: The vitamin B12 unit discrepancy (15 mg versus 15 mcg) is clinically material. Confirm the approved strength before use, sale or publication.
Store in the original, tightly closed packaging, protected from excessive heat, light and moisture, following the approved label. A specific temperature limit and shelf life must be supported by stability data. Keep out of reach of children.
For professional and B2B reference. Prescribing information, manufacturing claims, certification and market-specific approvals require verification.